Stable episomal vectors

Details Stable episomal vectors Stable episomal vectors

2007-11-13

2007-11-13

Woitach, Joseph (Department: 1633)

Chemistry: molecular biology and microbiology

Vector, per se

C435S070100, C435S325000, C424S093100, C514S04400A, C536S023100

Reexamination Certificate

active

10231467

ABSTRACT:
The present invention provides a vector system which can be stably translocated from the cytoplasm of a cell to the nucleus where it is a stable nuclear episomal vector. A basic vector system according to the present invention is generally composed of nucleic acid encoding (a) a promoter functional both in cytoplasm and nucleus, operably linked to (b) a plasmid maintenance/translocation factor and (c) an origin of replication.

REFERENCES:
patent: 5591601 (1997-01-01), Wagner et al.
patent: 6025155 (2000-02-01), Hadlaczky et al.
patent: 6046015 (2000-04-01), Goodman et al.
Langle-Rouault, et al. (1998) J. Virol., 72(7):6181-85.
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69□□.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Wolff, et al. (2001) Nature Biotech., 19: 1118-20.
Zanta, et al. (1999) Proc. Natl. Acad. Sci., USA., 96: 91-96.
Aiyar, et al. (1998) J. Biol. Chem., 273(49): 33073-81.
Yamamoto, et al. (1999) Virus Research, 65: 43-55.
Miyata, et al. (2000) Oncogene, 19: 1477-84.
Parnaik, et al. (1990) Molec. Cell. Biol., 10(3): 1287-92.
Belt et al., “Construction and properties of an Epstein-Barr-virus-derived cDNA expression vector for human cells”,Gene, 1989, pp. 407-417, vol. 84, Elsevier Science Publishers B. V. (Biochemical Division).
Mazda et al., “Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors”,Journal of Immunological Methods, 1997, pp. 143-151, vol. 204, Elsevier Science Publishers B. V.
Durocher et al., “High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells”,Nucleic Acids Research, 2002, pp. e 1-e9, vol. 30, No. 2, Oxford University press.
Rubanyi, “The future of human gene therapy”,Molecular Aspects of Medicine, 2001, pp. 113-142, vol. 22, Elsevier Science Ltd.
Langle-Rouault et al., “Up to 100-Fold Increase of Apparent Gene Expression in the Presence of Epstein-Barr VirusonP Sequences and EBNA1: Implications of the Nuclear Import of Plasmids.”, Journal of Virology, The American Society For Microbiology, vol. 72, No. 7, Jul. 1998, pp. 6181-6185, XP002924894 ISSN: 0022-538X.
M. Brisson et al., “A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes.”, Gene Therapy, vol. 6, No. 2, Feb. 1999, pp. 263-270, XP002302503, ISSN: 0969-7128.
S. Wang et al., “A novel herpesvirus amplicon system for in vivo gene delivery.”, Gene Therapy, vol. 4, No. 11, Nov. 1997, pp. 1132-1141, XP000964755, ISSN: 0969-7128.
Kathleen Van Craenenbroeck et al., “Episomal vectors for gene expression in mammalian cells.”, European Journal of Biochemistry, vol. 267, FEBS 2000, pp. 5665-5678, XP002954557, ISSN: 0014-2956.

Affiliated with

Also associated with

Rating

Stable episomal vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable episomal vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable episomal vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3822178